<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000632</url>
  </required_header>
  <id_info>
    <org_study_id>AVEG 005C</org_study_id>
    <secondary_id>10548</secondary_id>
    <nct_id>NCT00000632</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59</brief_title>
  <official_title>A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biocine</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and immune response of 100 mcg Env 2-3 antigen administered on days 0,&#xD;
      30, 180, and 365.&#xD;
&#xD;
      Preliminary immunologic data from protocol VEU 005B show evidence of the development of&#xD;
      functional antibodies in the form of increased peptide binding and development of&#xD;
      neutralizing antibodies. Evaluation of an antigen dose having potentially greater&#xD;
      immunogenicity is therefore of particular interest.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preliminary immunologic data from protocol VEU 005B show evidence of the development of&#xD;
      functional antibodies in the form of increased peptide binding and development of&#xD;
      neutralizing antibodies. Evaluation of an antigen dose having potentially greater&#xD;
      immunogenicity is therefore of particular interest.&#xD;
&#xD;
      Twelve healthy volunteers receive injections of 100 mcg Env 2-3 in MF59 emulsion and two&#xD;
      volunteers receive MF59 only on days 0, 30, 180, and 365. Follow-up continues for 6 months&#xD;
      after the last injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">May 1992</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">14</enrollment>
  <condition>HIV Infections</condition>
  <condition>HIV Seronegativity</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Env 2-3</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Subjects are:&#xD;
&#xD;
          -  Normal, healthy adults (by history and physical examination) who fully comprehend the&#xD;
             purpose and details of the study.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Subjects with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Positive syphilis serology (such as VDRL) unless positive test is due to a documented&#xD;
             clinical event that occurred and was treated 5 or more years prior to enrollment.&#xD;
&#xD;
          -  Circulating hepatitis B antigenemia.&#xD;
&#xD;
        Subjects with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of immunodeficiency, chronic illness, or autoimmune disease.&#xD;
&#xD;
          -  Evidence of depression or under treatment for psychiatric problems during the past&#xD;
             year.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Immunosuppressive medications.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Blood transfusions or cryoprecipitates within the past 6 months.&#xD;
&#xD;
        Identifiable high-risk behavior for HIV infection, including:&#xD;
&#xD;
          -  history of intravenous drug use; syphilis, gonorrhea, or any other sexually&#xD;
             transmitted diseases (including chlamydia or pelvic inflammatory disease) in the last&#xD;
             6 months; more than two sexual partners, or sexual contact with a high-risk partner,&#xD;
             in the preceding 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dolin R</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ. of Rochester AVEG</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Univ. Hosp. AVEG</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UW - Seattle AVEG</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>981050371</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Evans TG, Fitzgerald T, Gibbons DC, Keefer MC, Soucier H. Th1/Th2 cytokine responses following HIV-1 immunization in seronegative volunteers. The AIDS Vaccine Evaluation Group. Clin Exp Immunol. 1998 Feb;111(2):243-50. doi: 10.1046/j.1365-2249.1998.00486.x.</citation>
    <PMID>9486388</PMID>
  </reference>
  <reference>
    <citation>Keefer MC, Graham BS, McElrath MJ, Matthews TJ, Stablein DM, Corey L, Wright PF, Lawrence D, Fast PE, Weinhold K, Hsieh RH, Chernoff D, Dekker C, Dolin R. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses. 1996 May 20;12(8):683-93. doi: 10.1089/aid.1996.12.683.</citation>
    <PMID>8744579</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccines, Synthetic</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Adjuvants, Immunologic</keyword>
  <keyword>AIDS Vaccines</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

